头颈癌术后放疗间隔时间与生存的关联
该观察性队列研究基于美国国家癌症数据库(NCDB)25 216例非转移性III-IV期头颈鳞癌患者,分析术后至放疗开始时间(TS-RT)与总生存(OS)的关系。结果显示TS-RT≥50天与更差OS独立相关(HR 1.07),而43-49天未见显著死亡风险增加;扁桃体肿瘤延迟7天即与更差OS相关。
要点
- 头颈癌术后放疗间隔≥50天与更差总生存独立相关。
- 术后43-49天开始放疗未见显著死亡风险增加。
- 扁桃体肿瘤延迟7天即与更差生存相关,需优先安排。
核心结论
- 术后放疗间隔≥50天与更差总生存相关。
- 多学科团队应致力于缩短术后放疗间隔以改善生存。
- 不可避免的延迟可考虑加速分割或其他剂量强化策略。
研究设计与样本
- 观察性队列研究,纳入NCDB中25 216例非转移性III-IV期头颈鳞癌患者。
- 暴露为根治性手术后辅助放疗的间隔时间(TS-RT)。
- 主要结局为总生存(OS),并分析临床病理危险因素和加速分割的影响。
主要发现
- TS-RT≤42天患者中位OS为10.5年(95%CI 10.0-11.1)。
- TS-RT 43-49天患者中位OS为8.2年(95%CI 7.4-8.6),绝对差异-2.4年(95%CI -1.5至-3.2)。
- TS-RT≥50天患者中位OS为6.5年(95%CI 6.1-6.8),绝对差异-4.1年(95%CI -3.4至-4.7)。
- 多变量分析:与TS-RT≤42天比,43-49天死亡风险无显著增加(HR 0.98;95%CI 0.93-1.04),≥50天显著增加(HR 1.07;95%CI 1.02-1.12)。
- TS-RT与疾病部位存在显著交互作用;扁桃体肿瘤延迟7天与更差OS相关(HR 1.22;95%CI 1.05-1.43)。
关键数值与推荐
- NCCN推荐术后放疗应在6周内开始。
- TS-RT≥50天与更差OS独立相关(HR 1.07;95%CI 1.02-1.12)。
- 扁桃体肿瘤延迟7天与更差OS相关(HR 1.22;95%CI 1.05-1.43)。
- 加速分割≥5.2次/周与改善生存相关(HR 0.93;95%CI 0.87-0.99)。
临床怎么用
- 多学科团队应优化流程,尽量将术后放疗间隔缩短至50天以内。
- 对扁桃体肿瘤患者尤应优先安排放疗,避免延迟。
- 无法避免延迟时,可考虑加速分割或其他剂量强化策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Shortening the time from surgery to the start of radiation (TS-RT) is a consideration for physicians and patients. Although the National Comprehensive Cancer Network recommends radiation to start within 6 weeks, a survival benefit with this metric remains controversial. OBJECTIVE: To determine the association of delayed TS-RT with overall survival (OS) using a large cancer registry. DESIGN, SETTING, AND PARTICIPANTS: In this observational cohort study, 25 216 patients with nonmetastatic stages III to IV head and neck cancer were identified from the National Cancer Database (NCDB). EXPOSURES: Patients received definitive surgery followed by adjuvant radiation therapy, with an interval duration defined as TS-RT. MAIN OUTCOMES AND MEASURES: Overall survival as a function of TS-RT and the effect of clinicopathologic risk factors and accelerated fractionation. RESULTS: We identified 25 216 patients with nonmetastatic squamous cell carcinoma of the head and neck. There were 18 968 (75%) men and 6248 (25%) women and the mean (SD) age of the cohort was 59 (10.9) years. Of the 25 216 patients, 9765 (39%) had a 42-days or less TS-RT and 4735 (19%) had a 43- to 49-day TS-RT. Median OS was 10.5 years (95% CI, 10.0-11.1 years) for patients with a 42-days or less TS-RT, 8.2 years (95% CI, 7.4-8.6 years; absolute difference, -2.4 years, 95% CI, -1.5 to -3.2 years) for patients with a 43- to 49-day TS-RT, and 6.5 years (95% CI, 6.1-6.8 years; absolute difference, -4.1 years, 95% CI, -3.4 to -4.7 years) for those with a 50-days or more TS-RT. Multivariable analysis found that compared with a 42-days or less TS-RT, there was not a significant increase in mortality with a 43- to 49-day TS-RT (HR, 0.98; 95% CI, 0.93-1.04), although there was for a TS-RT of 50 days or more (HR, 1.07; 95% CI, 1.02-1.12). A significant interaction was identified between TS-RT and disease site. Subgroup effect modeling found that a delayed TS-RT of 7 days resulted in significantly worse OS for patients with tonsil tumors (HR, 1.22; 95% CI, 1.05-1.43) though not other tumor subtypes. Accelerated fractionation of 5.2 fractions or more per week was associated with improved survival (HR, 0.93; 95% CI, 0.87-0.99) compared with standard fractionation. CONCLUSIONS AND RELEVANCE: Delayed TS-RT of 50 days or more was associated with worse overall survival. The multidisciplinary care team should focus on shortening TS-RT to improve survival. Unavoidable delays may be an indication for accelerated fractionation or other dose intensification strategies.
引用
- Harris JP, Chen MM, Orosco RK, et al. Association of Survival With Shorter Time to Radiation Therapy After Surgery for US Patients With Head and Neck Cancer. JAMA Otolaryngol Head Neck Surg. 2018. PMID: 29522072. doi:10.1001/jamaoto.2017.3406
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。